• Shuttle Pharmaceuticals engaged Bush & Associates as its independent auditor on November 2, 2026, replacing Forvis Mazars.
• Forvis Mazars' dismissal takes effect following the filing of the quarterly report for the period ended September 30, 2026.
• Bush & Associates will audit the year ending December 31, 2026, and review interim financial statements for the first three quarters of 2027.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Shuttle Pharmaceuticals Holdings Inc. published the original content used to generate this news brief via EDGAR, the Electronic Data Gathering, Analysis, and Retrieval system operated by the U.S. Securities and Exchange Commission (Ref. ID: 0001493152-26-050532), on November 06, 2026, and is solely responsible for the information contained therein.